Mirna Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of micro ribonucleic acid (microRNA)-based oncology therapeutics. It is developing mimics of microRNAs that are designed to restore the tumor suppressor activity and aid tumor immune response, known as microRNA replacement therapy. Its lead product candidate, MRX34, is a mimic of microRNA 34 (miR 34) encapsulated in a liposomal nanoparticle formulation called SMARTICLES. miR 34 inhibits multiple oncogenic pathways, as well as stimulates anti-tumor immune response to induce cancer cell death. MRX34 entered clinical testing and is being studied in a multicenter, open-label Phase I trial in patients with primary liver cancer, other solid cancers and hematological malignancies. In various preclinical studies, miR 34 inhibited formation of cancer stem cells, which contribute to the development, metastasis and therapeutic resistance of tumors.